Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to -$5.0 million.

  • Ascendis Pharma A's Other Working Capital Changes fell 21024.32% to -$5.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.4 million, marking a year-over-year decrease of 703.99%. This contributed to the annual value of -$6.8 million for FY2025, which is 16157.9% down from last year.
  • As of Q4 2025, Ascendis Pharma A's Other Working Capital Changes stood at -$5.0 million, which was down 21024.32% from $34.4 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Other Working Capital Changes high stood at $38.8 million for Q2 2025, and its period low was -$10.9 million during Q1 2023.
  • In the last 5 years, Ascendis Pharma A's Other Working Capital Changes had a median value of -$1.0 million in 2021 and averaged $4.1 million.
  • In the last 5 years, Ascendis Pharma A's Other Working Capital Changes tumbled by 32765.63% in 2021 and then skyrocketed by 93512.71% in 2025.
  • Ascendis Pharma A's Other Working Capital Changes (Quarter) stood at -$3.4 million in 2021, then soared by 173.33% to $2.5 million in 2022, then plummeted by 321.85% to -$5.6 million in 2023, then soared by 181.95% to $4.6 million in 2024, then plummeted by 210.24% to -$5.0 million in 2025.
  • Its last three reported values are -$5.0 million in Q4 2025, $34.4 million for Q3 2025, and $38.8 million during Q2 2025.